AG真人官方

Tonix Pharmaceuticals (TNXP) reported cash and cash equivalents of $125.3 million, total assets of $187.4 million and stockholders' equity of $168.0 million at June 30, 2025, with working capital of approximately $124.5 million and an accumulated deficit of about $775.8 million. Product revenue totaled $2.0 million for the quarter (down from $2.2 million a year earlier) and $4.4 million for the six months (down from $4.7 million). The company reported a net loss of $28.3 million for the quarter and $45.1 million for the six months, driven by $16.2 million of selling, general and administrative expense and elevated R&D spending.

The company highlighted regulatory and pipeline progress: a PDUFA goal date of August 15, 2025 for TNX-102 SL with no FDA Advisory Committee meeting required and Fast Track designation; first patient enrolled in an ASD/ASR study in May 2025; positive Phase 1 topline for TNX-1500 supporting a Phase 2 kidney transplant program; and a DTRA contract for up to $34.1 million for TNX-4200 with $2.0 million of grant income recognized year-to-date. Management disclosed substantial doubt about going concern despite noting cash plus subsequent equity proceeds intended to fund operations into the third quarter of 2026.

Tonix Pharmaceuticals (TNXP) files Form 8-K with preliminary Q2 2025 figures.

• Cash & equivalents at 6/30/25: $125.3 million; shares outstanding 7/25/25: 8.75 million.
• Operating cash burn rose to $16.3 million from $9.9 million YoY.
• Capital expenditures were $1.1 million (prior-year: $0).
• Net operating loss narrowed sharply to $26.3 million versus $78.8 million in Q2 2024.
• Product revenue slipped to $2.0 million from $2.2 million.

Management says existing cash plus the $50.6 million equity raised in Q3 2025 should fund operations into Q3 2026, extending the runway by roughly 12 months.

All numbers are unaudited and subject to revision; EisnerAmper has performed no procedures. The full 10-Q is expected on or about 11 Aug 2025.

On 16 Jul 2025 Tonix Pharmaceuticals (NASDAQ: TNXP) filed a Form 8-K covering Item 7.01 (Reg FD) and Item 8.01 (Other Events). Management released an updated investor presentation (Exhibit 99.01) and revealed plans to deploy a 70-90 person U.S. sales force to commercialize its lead candidate TNX-102 SL for fibromyalgia if the FDA approves the pending New Drug Application. The materials are furnished, not filed, so they are excluded from Exchange Act liability and are not incorporated by reference into other SEC filings.

The filing contains no financial results, guidance or transactions. While the disclosure signals commercial readiness and confidence in the asset鈥檚 prospects, timing, cost, and regulatory outcome remain unspecified, leaving the near-term investment thesis largely unchanged.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) filed an 8-K to disclose new pre-clinical data for its TNX-801 recombinant horsepox vaccine candidate. The company presented the findings at Vaccine Congress 2025 and furnished both a press release (Ex. 99.01) and slide deck (Ex. 99.02) under Items 7.01 and 8.01. Key highlights:

• Durable, single-dose immunity: A single injection produced strong binding and neutralising antibody responses across multiple animal models, including immunocompromised subjects.
• Highly attenuated safety profile: In primary human dermal cells the virus replicates 27- to 119-fold less than licensed vaccinia strains; in IFN-receptor knockout mice it is up to 100,000-fold less virulent.
• Protection data: All vaccinated macaques survived lethal Clade I mpox challenge without lesions; rabbits remained protected for 14 months.
• Administration advantage: Subcutaneous delivery showed equivalent protection to the standard percutaneous route and may reduce bacterial super-infection, scarring, and inadvertent virus spread.
• Strategic positioning: Management believes TNX-801 could become a critical counter-measure against mpox outbreaks and bioterror-related smallpox re-introduction.

The disclosure contains only forward-looking statements, no financial metrics, and the information is furnished, not filed, limiting legal liability. While the data strengthen the scientific rationale, the asset remains at a pre-clinical stage and faces regulatory, funding, and competitive uncertainties.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) filed an 8-K to disclose new pre-clinical data on its oncology candidate TNX-1700. A peer-reviewed paper published in Cancer Cell shows the murine analogue, mTNX-1700鈥攁 fusion of murine TFF2 and serum albumin鈥�extended survival and reduced metastases in gastric-cancer animal models. The Company believes the findings support further development of the human version, which is being explored for gastric and colorectal cancers and as a means to overcome resistance to anti-PD-1 immunotherapy. The publication is the product of a collaboration with Columbia University鈥檚 Vagelos College of Physicians and Surgeons.

The disclosure is delivered under Item 7.01 (Regulation FD) and Item 8.01 (Other Events); no financial metrics, guidance, or contractual commitments were included. Management emphasizes that the information is furnished, not filed, thereby limiting potential liability. Forward-looking-statement language highlights typical development risks and underscores that results are limited to animal studies.